CONFLICT OF INTEREST STATEMENT
EPS
Ono Pharmaceutical Co., Ltd. and Bristol‐Myers Squibb funded the study, provided the study drugs, and were involved in the collection, analysis, and interpretation of the data. Employees of the sponsors reviewed and commented on the manuscript. The authors had full access to the data and took final responsibility for the decision to publish the manuscript.The authors report the following disclosures; remuneration of 1 million yen or more: S.T. (Ono Pharmaceutical); lecture fees/honoraria/other fees of 500,000 yen or more: H.‐R.K. (Ono Pharmaceutical, AstraZeneca, Roche, Boehringer Ingelheim), S.S. (Ono Pharmaceutical, Bristol‐Myers Squibb), T.H. (Ono Pharmaceutical, Bristol‐Myers Squibb), K.‐H.L. (Bristol‐Myers Squibb, MSD, AstraZeneca, Pfizer, and Eli Lilly), T.Y. (Ono Pharmaceutical, Chugai, AstraZeneca), H.T. (AstraZeneca, Chugai), C.‐T.Y. (Ono Pharmaceutical, Boehringer Ingelheim, AstraZeneca, Chugai, Pfizer, Takeda, Novartis, Roche, Eli Lilly, Merck, MSD), M.N. (Ono Pharmaceutical, Bristol‐Myers Squibb), Y.O. (AstraZeneca, Chugai), T.T. (Cmic ShiftZero), H.A. (AstraZeneca), N.Y. (MSD, AstraZeneca, Chugai, Eli Lilly, Boehringer‐Ingelheim, Pfizer, Ono Pharmaceutical, Takeda), K.N. (Eli Lilly, Chugai, Ono Pharmaceutical); annual contract research grants of 1 million yen or more: H.‐R.K (Ono Pharmaceutical), S.S. (Ono Pharmaceutical, Bristol‐Myers Squibb), J.‐S.L. (Ono Pharmaceutical), J.‐H.K. (Ono Pharmaceutical), N.I. (Ono Pharmaceutical), T.H. (Ono Pharmaceutical, Bristol‐Myers Squibb), K.‐H.L. (Ono Pharmaceutical), T.Y. (Ono Pharmaceutical, Chugai, AstraZeneca, Amgen, Novartis, Bristol‐Myers Squibb, Takeda), H.T. (Ono Pharmaceutical), C.‐T.Y. (Ono Pharmaceutical), M.N. (Ono Pharmaceutical, Bristol‐Myers Squibb), Y.O. (AstraZeneca, Chugai, Eli Lilly, Ono Pharmaceutical, Bristol‐Myers Squibb, Kirin, Dainippon‐Sumitomo, Pfizer, Taiho, Novartis, Takeda, Kissei, Daiichi‐Sankyo, Janssen, LOXO), N.Y. (Chugai, Toppan printing, Cmic ShiftZero, MSD, Pfizer, PPD, IQVIA, Eli Lilly, A2 healthcare, Boehringer Ingelheim, Terumo, Takeda, AstraZeneca, Amgen, Jansen, Taiho, Ono Pharmaceutical), C.‐J.Y. (Ono Pharmaceutical), H.A. (Chugai, Amgen), K.N. (Ono Pharmaceutical, MSD, Daiichi Sankyo, Taiho, Chugai, SYNEOS HEALTH CLINICAL, Japan Clinical Research Operations, AstraZeneca, IQVIA Services JAPAN, Covance Japan, Takeda, GlaxoSmithKline, Sanofi, EPS Corporation, Novartis, Medical Research Support); scholarship/endowments of 1 million yen or more: N.Y. (Taiho, Chugai, Daiichi‐Sankyo, Ono Pharmaceutical), K.N. (Takeda, Chugai, Ono Pharmaceutical). Y.O. is a member of the editorial board of 